title: The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management.
abstract: Clozapine, the first atypical antipsychotic, is indicated for the treatment of therapy-resistant schizophrenia. It needs to be monitored closely because of its well-known potential side-effects, especially agranulocytosis. We present a case of a middle-aged woman with chronic schizophrenia, who was treated with clozapine and developed a clinical syndrome of asymptomatic pancreatitis and eosinophilia within the fifth week of treatment. Asymptomatic pancreatitis has rarely been reported up to now and is not recognized as a typical side-effect of clozapine. In our opinion, pancreatic enzymes should be monitored especially in the first 6 weeks of clozapine treatment.
authors.affiliation: Department of Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany. Garlipp.Petra@mh-hannover.de
authors.forename: P
authors.initials: P
authors.lastname: Garlipp
authors.forename: O
authors.initials: O
authors.lastname: Rosenthal
authors.forename: H
authors.initials: H
authors.lastname: Haltenhof
authors.forename: W
authors.initials: W
authors.lastname: Machleidt
mesh_terms: D000328:Adult; D000681:Amylases / Q000097:blood; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D004802:Eosinophilia / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D010195:Pancreatitis / Q000139:chemically induced* / Q000175:diagnosis; D020799:Pancrelipase / Q000097:blood; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D020799:Pancrelipase; D000681:Amylases; D003024:Clozapine